Eccogene, Enters

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Published on 08/07/2025 at 18:03 | prnewswire.co.uk

Eccogene, Inc. China Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/eccogene-enters-exclusive-license-agreement-with-astrazeneca-to-develop-and-commercialize-small-molecule-glp-1-receptor-agonist-ecc5004-for-cardiometabolic-diseases-301982798.html

en | GB0009895292 | ECCOGENE | boerse | 67994351 |